FGFR1 and neoplasm: Finally, among 391 patients in MONALEESA-2 with tumor gene expression data, those with higher FGFR1 mRNA expression levels have so far exhibited a statistically significant shorter PFS than those with lower FGFR1 mRNA expression levels, consistent with and supportive of the ctDNA NGS finding.